Pharmafocus (@Pharmafocus) profile picture

Pharmafocus

@Pharmafocus

Pharmafocus Magazine - covering pharma and biotech since 1986.

pharmafocus.com
Joined December 2008
  • Tweets27.4K
  • Following1.7K
  • Followers48.2K
7.4KMedia
Photo by Pharmafocus (@Pharmafocus)Photo by Pharmafocus (@Pharmafocus)Photo by Pharmafocus (@Pharmafocus)Photo by Pharmafocus (@Pharmafocus)Photo by Pharmafocus (@Pharmafocus)Photo by Pharmafocus (@Pharmafocus)Photo by Pharmafocus (@Pharmafocus)Photo by Pharmafocus (@Pharmafocus)Photo by Pharmafocus (@Pharmafocus)Photo by Pharmafocus (@Pharmafocus)
Dermatology leader Doncker is new Onicor CEO pharmafile.com/appointments/…
Dermatology leader Doncker is new Onicor CEO - Pharmafile

Dermatology leader Doncker is new Onicor CEO - Pharmafile

Onicor, a medical technology company developing a personalised treatment for onychomycosis (fungal nail infection), has appointed Piet De Doncker as its new

pharmafile.com
1
360
East London pharmacies pilot cholesterol-lowering injections to cut waiting times pharmafile.com/news/east-lon…
East London pharmacies pilot cholesterol-lowering injections to cut waiting times - Pharmafile

East London pharmacies pilot cholesterol-lowering injections to cut waiting times - Pharmafile

A pilot scheme in east London is offering cholesterol-lowering injections at community pharmacies to help patients access treatment sooner and ease pressure

pharmafile.com
255
Weber is new CMO at Sensorion pharmafile.com/appointments/…
Weber is new CMO at Sensorion - Pharmafile

Weber is new CMO at Sensorion - Pharmafile

Otologist and neurotologist Dr. Peter Weber has been appointed Chief Medical Officer of biotech Sensorion.

pharmafile.com
1
373
Breast Cancer Now commits £800,000 to AI research into late breast cancer recurrence pharmafile.com/news/breast-c…
Breast Cancer Now commits £800,000 to AI research into late breast cancer recurrence - Pharmafile

Breast Cancer Now commits £800,000 to AI research into late breast cancer recurrence - Pharmafile

Breast Cancer Now is investing £800,000 in two research projects using artificial intelligence (AI) to investigate why oestrogen receptor-positive

pharmafile.com
1
377
AstraZeneca’s Trixeo approved in EU for asthma in patients aged 12 and over pharmafile.com/news/astrazen…
AstraZeneca’s Trixeo approved in EU for asthma in patients aged 12 and over - Pharmafile

AstraZeneca’s Trixeo approved in EU for asthma in patients aged 12 and over - Pharmafile

AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved by the European Commission as a maintenance

pharmafile.com
1
364
Acumentis CEO Herspiegel steps down as Burden assumes role pharmafile.com/appointments/…
Acumentis CEO Herspiegel steps down as Burden assumes role - Pharmafile

Acumentis CEO Herspiegel steps down as Burden assumes role - Pharmafile

Ramil Burden is the new Chief Executive Officer of Acumetis, announced the company in a recent statement. 

pharmafile.com
387
Sobi’s olezarsen recommended for EU approval in severe hypertriglyceridaemia pharmafile.com/news/sobis-ol…
Sobi’s olezarsen recommended for EU approval in severe hypertriglyceridaemia - Pharmafile

Sobi’s olezarsen recommended for EU approval in severe hypertriglyceridaemia - Pharmafile

Sobi’s olezarsen (TRYNGOLZA) has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP),

pharmafile.com
1
336
Hot-tub therapy tested as potential treatment for peripheral artery disease pharmafile.com/news/hot-tub-…
Hot-tub therapy tested as potential treatment for peripheral artery disease - Pharmafile

Hot-tub therapy tested as potential treatment for peripheral artery disease - Pharmafile

Researchers at Manchester Metropolitan University are investigating whether regular hot-water immersion can improve mobility and relieve pain in people with

pharmafile.com
299
Raimond takes helm at Nuclera pharmafile.com/appointments/…
Raimond takes helm at Nuclera - Pharmafile

Raimond takes helm at Nuclera - Pharmafile

Nuclera, the biotechnology company enabling access to innovative protein technologies, has appointed Carl Raimond as Chief Executive Officer, effective

pharmafile.com
391
Most advanced breast cancer patients treated in community settings, Phesi study finds pharmafile.com/news/most-adv…
Most advanced breast cancer patients treated in community settings, Phesi study finds - Pharmafile

Most advanced breast cancer patients treated in community settings, Phesi study finds - Pharmafile

Most patients with advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer are treated in community settings rather than academic centres,

pharmafile.com
325
Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison pharmafile.com/news/orforgli…
Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison -...

Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison -...

Pharmaceutical firm Lilly’s orforglipron was associated with greater reductions in body weight and blood glucose than oral semaglutide in adults with type 2

pharmafile.com
1
1
1
405
The extended deadline for the EHP Awards 2027 is here! If you are finalising your submission or interested in entering but concerned about meeting the deadline, please contact [email protected] for assistance. Enter here: ehpawards.com/how-to-enter #EHPAwards
Image from Pharmafocus (@Pharmafocus)
269
Bramacare opens supported-living facility for eating disorder recovery pharmafile.com/news/bramacar…
Bramacare opens supported-living facility for eating disorder recovery - Pharmafile

Bramacare opens supported-living facility for eating disorder recovery - Pharmafile

Bramacare has opened a new facility in Ipswich offering supported living for adults recovering from complex eating disorders, providing a transitional stage

pharmafile.com
283
Aiforia deal to expand access to pathology AI pharmafile.com/news/aiforia-…
Aiforia deal to expand access to pathology AI - Pharmafile

Aiforia deal to expand access to pathology AI - Pharmafile

Aiforia has signed a commercial agreement with PathAI to make its artificial intelligence (AI) solutions for digital pathology available to laboratories

pharmafile.com
484
SMC accepts atogepant for acute migraine treatment in Scotland pharmafile.com/news/smc-acce…
SMC accepts atogepant for acute migraine treatment in Scotland - Pharmafile

SMC accepts atogepant for acute migraine treatment in Scotland - Pharmafile

The Scottish Medicines Consortium (SMC) has accepted AbbVie’s Aquipta (atogepant) as an option for the acute treatment of migraine with or without aura in

pharmafile.com
1
486
New CCO Ogburn joins Cori Clinical pharmafile.com/appointments/…
New CCO Ogburn joins Cori Clinical - Pharmafile

New CCO Ogburn joins Cori Clinical - Pharmafile

Cori Clinical has announced the appointment of Dr Emma Ogburn as Chief Clinical Officer. She joins Cori’s founding team of industry veterans, including CEO

pharmafile.com
422
Claris reports visual acuity gains with experimental LSCD treatment pharmafile.com/news/claris-r…
Claris reports visual acuity gains with experimental LSCD treatment - Pharmafile

Claris reports visual acuity gains with experimental LSCD treatment - Pharmafile

Claris Biotherapeutics has reported visual acuity improvements with its experimental therapy CSB-001 in a proof-of-concept study involving patients with

pharmafile.com
1
317
Amphista doses first patient in AML trial of protein degrader pharmafile.com/news/amphista…
Amphista doses first patient in AML trial of protein degrader - Pharmafile

Amphista doses first patient in AML trial of protein degrader - Pharmafile

Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an experimental oral therapy targeting acute myeloid leukaemia (AML) and

pharmafile.com
1
400
First 90 days of antipsychotic treatment linked to rapid metabolic changes pharmafile.com/news/first-90…
First 90 days of antipsychotic treatment linked to rapid metabolic changes - Pharmafile

First 90 days of antipsychotic treatment linked to rapid metabolic changes - Pharmafile

The first 90 days after starting antipsychotic treatment are a critical period for monitoring blood glucose and weight, according to a study led by University

pharmafile.com
238
Jennings becomes President of Beckman Coulter Diagnostics pharmafile.com/appointments/…
Jennings becomes President of Beckman Coulter Diagnostics - Pharmafile

Jennings becomes President of Beckman Coulter Diagnostics - Pharmafile

Beckman Coulter Diagnostics has appointed Catherine Jennings as its new President. 

pharmafile.com
405
Load more